JPMorgan analyst James Gordon lowered the firm’s price target on Genmab (GMAB) to DKK 1,700 from DKK 2,050 and keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
Questions or Comments about the article? Write to editor@tipranks.com